Abstract
This review is focused on the role of Focal Adhesion Kinase (FAK) signaling in cancer stem cells. The recent data demonstrate the important role of FAK in cancer stem cell proliferation, differentiation, motility, and invasion. We showed recently that the transcription factor Nanog binds the FAK promoter and up-regulates FAK expression, and that FAK binds Nanog and phosphorylates it. This review discusses the interaction of FAK, Nanog, Oct-3/4, and Sox-2 signaling pathways that are critical for the regulation of cancer stem cells. The cross-linked signaling of FAK with p53 and Nanog signaling in cancer stem cell and function and targeted therapeutics approaches are discussed.
Keywords: Adhesion, Cancer, Focal Adhesion Kinase, Inhibitor, Metastasis, Tumor
Anti-Cancer Agents in Medicinal Chemistry
Title:FAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Volume: 13 Issue: 4
Author(s): Vita M. Golubovskaya
Affiliation:
Keywords: Adhesion, Cancer, Focal Adhesion Kinase, Inhibitor, Metastasis, Tumor
Abstract: This review is focused on the role of Focal Adhesion Kinase (FAK) signaling in cancer stem cells. The recent data demonstrate the important role of FAK in cancer stem cell proliferation, differentiation, motility, and invasion. We showed recently that the transcription factor Nanog binds the FAK promoter and up-regulates FAK expression, and that FAK binds Nanog and phosphorylates it. This review discusses the interaction of FAK, Nanog, Oct-3/4, and Sox-2 signaling pathways that are critical for the regulation of cancer stem cells. The cross-linked signaling of FAK with p53 and Nanog signaling in cancer stem cell and function and targeted therapeutics approaches are discussed.
Export Options
About this article
Cite this article as:
M. Golubovskaya Vita, FAK and Nanog Cross Talk with p53 in Cancer Stem Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1871520611313040006
DOI https://dx.doi.org/10.2174/1871520611313040006 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Reactions of Hydrazones with Lead Tetraacetate in Organic Synthesis
Current Organic Chemistry Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology MicroRNAs as Cancer Biomarkers
MicroRNA Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Recent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Recent Patents on Regenerative Medicine Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued)